Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | LSS | P48449 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14715270 | 0.84 | CA9 (0.56) | CA9ALDH1A1LMNASMN1; SMN2PKM | |
| SCHEMBL525331 | 0.80 | IDO1 (0.62) | ALDH1A1LMNASMN1; SMN2KDM4EGAA | |
| SCHEMBL17178075 | 0.79 | CA9 (0.54) | CA9ALDH1A1LMNASMN1; SMN2PKM | |
| SCHEMBL10310272 | 0.79 | ALDH1A1 (0.47) | CA9ALDH1A1LMNASMN1; SMN2MAPT | |
| SCHEMBL14715269 | 0.79 | CA9 (0.54) | CA9ALDH1A1LMNASMN1; SMN2PKM | |
| SCHEMBL6929919 | 0.79 | RECQL (0.62) | ALDH1A1LMNASMN1; SMN2MAPTGAA | |
| SCHEMBL133802 | 0.78 | ALOX12 (0.68) | CA9ALDH1A1LMNASMN1; SMN2PKM | |
| SCHEMBL22365688 | 0.78 | KEAP1 (0.56) | CA9ALDH1A1LMNASMN1; SMN2PKM | |
| Iodide SCHEMBL20524285 | 0.78 | RECQL (0.61) | ALDH1A1SMN1; SMN2MAPTGAAHSD17B10 | |
| SCHEMBL525353 | 0.77 | ALDH1A1 (0.74) | ALDH1A1LMNASMN1; SMN2KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118108664-A | NAMPT agonist and preparation method and application thereof | 中国人民解放军海军军医大学 | 2024-05-31 | — | — | CN | claimed |
| US-9353089-B2 | Compositions and methods for the treatment of malaria | SAINT LOUIS UNIVERSITY (US) | 2016-05-31 | — | — | US | disclosed |
| US-9150561-B2 | Thiazole derivatives and use thereof | MERCK SERONO S.A. (CH) | 2015-10-06 | — | — | US | disclosed |
| WO-2014160775-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MALARIA | SAINT LOUIS UNIVERSITY (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140296532-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MALARIA | GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2014-10-02 | — | — | US | disclosed |
| US-20140228365-A1 | THIAZOLE DERIVATIVES AND USE THEREOF | MERCK SERONO S.A. (CH) | 2014-08-14 | — | — | US | disclosed |
| US-8802861-B2 | Thiazole derivatives and use thereof | MERCK SERONO SA (CH) | 2014-08-12 | — | — | US | disclosed |
| EP-2611777-A1 | 4- { [ ( PYRIDIN- 3 - YL -METHYL) AMINOCARBONYL]AMINO} BENZENE - SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER | Forma TM, LLC. (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-2010535-B1 | THIOXANTHINE DERIVATIVES AND THEIR USE AS INHIBITORS OF MPO | ASTRAZENECA AB (SE) | 2012-07-11 | — | — | EP | disclosed |
| WO-2012031196-A1 | 4- { [ ( PYRIDIN- 3 - YL -METHYL) AMINOCARBONYL] AMINO} BENZENE - SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| CN-101466712-A | Thioxanthine derivatives and their use as inhibitors of mpo | ASTRAZENECA AB (SE) | 2009-06-24 | — | — | CN | disclosed |
| US-20090149475-A1 | Thioxanthine Derivatives and Their Use as Inhibitors of MPO | ASTRAZENECA AB (SE) | 2009-06-11 | — | — | US | disclosed |
| US-20090029998-A1 | Thiazole Derivatives and Use Thereof | APPLIED RESEARCH SYSTEM ARS HOLDING N.V. (NL) | 2009-01-29 | — | — | US | disclosed |
| EP-2010535-A1 | THIOXANTHINE DERIVATIVES AND THEIR USE AS INHIBITORS OF MPO | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007120098-A1 | THIOXANTHINE DERIVATIVES AND THEIR USE AS INHIBITORS OF MPO | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | disclosed |
| EP-1709019-B1 | THIAZOLE DERIVATIVES AND USE THEREOF | APPLIED RESEARCH SYSTEMS (AN) | 2007-08-08 | — | — | EP | disclosed |
| EP-1709019-A2 | THIAZOLE DERIVATIVES AND USE THEREOF | Applied Research Systems ARS Holding N.V. (AN) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005068444-A2 | THIAZOLE DERIVATIVES AND USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-07-28 | — | — | WO | disclosed |
| CN-1019393-B | Substituted N-[(4-piperidingl] alkyl] bicyclic condensed oxazol and thiazolaminer | JANSSEN PHARMACEUTICA NV (BE) | 1992-12-09 | — | — | CN | disclosed |
| CN-86102349-A | Preparation N-[(4-piperidyl) alkyl] the bicyclic condensed azoles that replaces and the method for thiazole amine | — | 1986-11-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228365-A1 | THIAZOLE DERIVATIVES AND USE THEREOF | PF4, TEC, PDGFRB | CA9 1678/4885ALDH1A1 234/4885LMNA 4675/4885 |
| US-20090029998-A1 | Thiazole Derivatives and Use Thereof | PDGFRB, PDGFRA, TEC | CA9 3061/4885ALDH1A1 174/4885LMNA 4765/4885 |
| US-20140296532-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MALARIA | BACE2, DNPEP, ACE | CA9 627/4885ALDH1A1 1822/4885LMNA 1932/4885 |
| US-20090149475-A1 | Thioxanthine Derivatives and Their Use as Inhibitors of MPO | MPO, XDH, EPX | CA9 2195/4885ALDH1A1 309/4885LMNA 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.